EZH2 and lymphangioma: These two elegant study together suggested the specific immune microenvironment of LM and ICI based combination therapy (e.g. plus CTLA-4 inhibitor, EZH2 inhibitors, radiotherapy, etc.)could rescue systemic antitumor immunity and improve the prognosis of cancer patients with LM.